To Compare The Effects Of Empagliflozin And Metformin On Serum Vitamin D Levels In Patients With Metabolic Syndrome.
DOI:
https://doi.org/10.36283/ziun-pjmd15-1/027Keywords:
Empagliflozin, Metformin, Type 2 Diabetes Mellitus, Glycemic Control, Lipid Profile, Bone Health, Cardiovascular DiseasesAbstract
Background: Metabolic Syndrome (MetS) is a cluster of metabolic conditions with increased risk to cardiovascular disease and type 2 diabetes mellitus T2DM. Recent researches have also proposed a relationship between MetS and vitamin D insufficiency. Empagliflozin and Metformin are commonly prescribed for treating MetS; however, their comparative impact on serum vitamin D level remains unclear. The aim of the study was to assess and compare the impact of empagliflozin and metformin on serum vitamin D levels in patients with MetS.
Methods: A comparative study was carried out involving 100 patients diagnosed with T2DM, who were assigned to receive Empagliflozin (Group A) & Metformin (Group B). The variables, including weight, BMI, waist-hip ratio (WHR), blood pressure, fasting blood sugar (FBS), lipid profile and Serum Vitamin D, were recorded, before and after treatment. Statistical analysis was performed using SPSS v23 to assess group differences.
Results: After treatment, the Metformin group showed significant reduction in weight and BMI (p < 0.05), while Empagliflozin group had greater reduction in WHR and Blood pressure (p < 0.05). glycemic control improved significantly in both groups, with a slightly greater FBS reduction in the metformin group (p < 0.05). Empagliflozin significantly increased Vitamin D levels (p < 0.001), whereas Metformin reduced them.
Conclusion: both drugs improved glycemic control, but Empagliflozin had added benefits on central obesity, blood pressure, lipid profile, and Vitamin D levels, highlighting its potential extra-metabolic effects and the need for further long-term research.
References
1. Neeland IJ, Lim S, Tchernof A, Gastaldelli A, Rangaswami J, Ndumele CE, Powell-Wiley TM, Després JP. Metabolic syndrome. Nat Rev Dis Primers. 2024 Oct 17;10(1):77. doi: 10.1038/s41572-024-00563-5. PMID: 39420195.
2. Pirih FQ, Monajemzadeh S, Singh N, Sinacola RS, Shin JM, Chen T, Fenno JC, Kamarajan P, Rickard AH, Travan S, Paster BJ, Kapila Y. Association between metabolic syndrome and periodontitis: The role of lipids, inflammatory cytokines, altered host response, and the microbiome. Periodontol 2000. 2021 Oct;87(1):50-75. doi: 10.1111/prd.12379. PMID: 34463996; PMCID: PMC8457155.
3. Ahmed A, Akhter J, Iqbal R, Jabbar A, Mawani M, Awan S, Samad Z, Shaikh PA, Salik M, Tuomilehto J. Prevalence and Associations of Metabolic Syndrome in an Urban High Diabetes Risk Population in a Low/Middle-Income Country. Metab Syndr Relat Disord. 2020 Jun;18(5):234-242. doi: 10.1089/met.2019.0098. Epub 2020 May 4. PMID: 32366202.
4. Hussain, Z.; Mehmood, S. Prevalence of metabolic syndrome: Its risk factors and viral hepatitis B & C in underprivileged suburban population of Lahore, Pakistan. Prof. Med. J. 2021, 23, 434–443. DOI: https://doi.org/10.29309/TPMJ/2016.23.04.1502
5. Gallardo-Alfaro, L.; Bibiloni, M.d.M.; Mascaró, C.M.; Montemayor, S.; Ruiz-Canela, M.; Salas-Salvadó, J.; Corella, D.; Fitó, M.; Romaguera, D.; Vioque, J.; et al. Leisure-Time Physical Activity, Sedentary Behaviour and Diet Quality Are Associated with Metabolic Syndrome Severity: The PREDIMED-Plus Study. Nutrients 2020, 12, 1013. DOI: 10.3390/nu12041013
6. Bhupathiraju, S.N.; Hu, F.B. Epidemiology of Obesity and Diabetes and Their Cardiovascular Complications. Circ. Res. 2016, May, 118, 1723–1735. DOI: 10.1161/CIRCRESAHA.115.306825
7. Denisenko, Y.K.; Kytikova, O.Y.; Novgorodtseva, T.P.; Antonyuk, M.V.; Gvozdenko, T.A.; Kantur, T.A. Lipid-Induced Mechanisms of Metabolic Syndrome. J. Obes. 2020, 2020, Aug, 5762395. DOI: 10.1155/2020/5762395
8. Scholtes RA, Mosterd CM, Hesp AC, Smits MM, Heerspink HJ, van Raalte DH. Mechanisms underlying the blood pressure‐lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial. Diabetes, Obesity and Metabolism. 2023 Jan;25(1):198-207. doi: 10.1111/dom.14864
9. Fayette L, Sailer MO, Perez‐Pitarch A. Pharmacometrics enhanced Bayesian borrowing approach to improve clinical trial efficiency: Case of empagliflozin in type 2 diabetes. CPT: Pharmacometrics & Systems Pharmacology. 2023. OCT, doi: 10.1002/psp4.13035.
10. Khan RA, Patel N, Folajimi A, Bai BR, Patel V, Komminni PK, Palleti SK, Hirani S, Atunde FJ, Patel VP. Comparison of the Efficacy and Safety of Metformin-Based Combination Therapy Versus Metformin Alone in Children and Adolescents with Type 2 Diabetes Mellitus: A Meta-Analysis. Cureus. 2023 Feb 15;15(2). doi: 10.7759/cureus.35014
11. Donnan K, Segar L. SGLT2 inhibitors and metformin: dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol. 2019 Jan ;846:23–9. doi: 10.1016/j.ejphar.2019.01.002.
12. Raposo L, Martins S, Ferreira D, Guimarães JT, Santos AC. Vitamin D, parathyroid hormone and metabolic syndrome - the PORMETS study. BMC Endocr Disord. 2017 Nov 17;17(1):71. doi: 10.1186/s12902-017-0221-3. PMID: 29149839; PMCID: PMC5693479.
13. Illescas-Montes, R.; Melguizo-Rodríguez, L.; Ruiz, C.; Costela-Ruiz, V.J. Vitamin D and Autoimmune Diseases. Life Sci. 2019 Nov, 233, 116744. DOI: 10.1016/j.lfs.2019.116744
14. Melguizo-Rodríguez L, Costela-Ruiz VJ, García-Recio E, De Luna-Bertos E, Ruiz C, Illescas-Montes R. Role of vitamin D in the metabolic syndrome. Nutrients. 2021 Mar 3;13(3):830. DOI: 10.3390/nu13030830
15. Adil SO, Islam MA, Musa KI, Shafique K. Prevalence of Metabolic Syndrome among Apparently Healthy Adult Population in Pakistan: A Systematic Review and Meta-Analysis. Healthcare (Basel). 2023 Feb 10;11(4):531. doi: 10.3390/healthcare11040531. PMID: 36833064; PMCID: PMC9957355.
16. Gallardo-Alfaro, L.; Bibiloni, M.d.M.; Mascaró, C.M.; Montemayor, S.; Ruiz-Canela, M.; Salas-Salvadó, J.; Corella, D.; Fitó, M.; Romaguera, D.; Vioque, J.; et al. Leisure-Time Physical Activity, Sedentary Behaviour and Diet Quality Are Associated with Metabolic Syndrome Severity: The PREDIMED-Plus Study. Nutrients 2020, 12, 1013. DOI: 10.3390/nu12041013
17. Wilkinson, M.J.; Manoogian, E.N.C.; Zadourian, A.; Lo, H.; Fakhouri, S.; Shoghi, A.; Wang, X.; Fleischer, J.G.; Navlakha, S.; Panda, S.; et al. Ten-Hour Time-Restricted Eating Reduces Weight, Blood Pressure, and Atherogenic Lipids in Patients with Metabolic Syndrome. Cell Metab. 2020,Jan 31, 92–104.e5. DOI: 10.1016/j.cmet.2019.11.004
18. Abu el Maaty MA, Hanafi RS, Aboul-Enein HY, Gad MZ. Design-of-experiment approach for HPLC analysis of 25-hydroxyvitamin D: a comparative assay with ELISA. Journal of chromatographic science. 2015 Jan 1;53(1):66-72. DOI: 10.1093/chromsci/bmu017
19. Ding X, long F, Chen L, et al. Interaction of tea drinking and healthy lifestyle on the prevalence of diabetes among residents aged 30 to 79 in Chongqing. Pract Prev Med. 2022 Mar;29(6):641–4. DOI: 10.2147/IJGM.S401889
20. Neeland IJ, McGuire DK, Chilton R, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016 Mar; 13: 119-126. DOI: 10.1177/1479164115616901
21. Traina S, Guthrie R, Slee A. The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes. Postgrad Med. 2014 May; 126: 7-15. DOI: 10.3810/pgm.2014.05.2752
22. Ross SA, Dzida G, Vora J, Khunti K, Kaiser M, Ligthelm RJ. Impact of weight gain on outcomes in type 2 diabetes. Curr Med Res Opin. 2011 Jul; 27: 1431-1438. DOI: 10.1185/03007995.2011.585396
23. Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes ObesMetab. 2015 Dec; 17: 1180-1193. DOI: 10.1111/dom.12572
24. Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diabetes and vascular disease Research. 2015 Mar;12(2):90-100. DOI: 10.1177/1479164114559852
25. Briand F, Mayoux E, Brousseau E, Burr N, Urbain I, Costard C, et al. Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism. Diabetes 2016 Jul;65:2032–8. DOI: 10.2337/db16-0049
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
Metrics
How to Cite
